Quest Diagnostics Inc.’s (DGX) first-quarter 2025 adjusted earnings per share (EPS) of $2.21 beat the Zacks Consensus Estimate by 2.8%. The metric also exceeded the year-ago adjusted figure by 8.3%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adj ...

Quest Diagnostics (DGX) Q1 2025 Earnings Call April 22, 2025 08:30 AM ET Company Participants Shawn Bevec - VP of IRJames Davis - Chairman, CEO & PresidentSam Samad - Executive VP & CFOKevin Caliendo - Managing DirectorPatrick Donnelly - Managing DirectorNoah Kava - Equity Research AssociateMichael Ryskin - Managing Director Conference Call Participants Luke Sergott - AnalystElizabeth Anderson - AnalystMichael Cherny - Senior Managing Director & Senior Research AnalystPito Chickering - AnalystDavid Westenbe ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.79%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.19 per share when it actually produced earnings of $2.23, delivering a surprise of 1.83%.Over the last four qua ...

"In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access," said Jim Davis, Chairman, CEO and President. "We are reaffirming our revenue and adjusted EPS guidance for the full year 2025." | | | | | Three Mont ...

First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announce ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rele ...

Quest Diagnostics (DGX) is set to release its first-quarter 2025 results on April 22, before the market opens.The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.23 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.83%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.75%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)DGX’s Q1 EstimatesFor the first quarter of 2025, ...

文章核心观点 公司推出新血液检测助力医生确认阿尔茨海默病患者脑淀粉样蛋白病理情况，该检测准确性高且有研究支持，能扩大优质AD评估途径 [1][6][10] 新检测介绍 - 新检测名为AD - Detect™ Abeta 42/40 and p - tau217 Evaluation，结合两种血液蛋白水平检测结果生成AD - Detect Likelihood Score™ [2] - 新检测基于之前的AD - Detect测试，之前测试评估风险，新测试确认脑淀粉样蛋白病理可能性 [3] 研究成果 - 研究表明新测试在轻度认知障碍人群中阳性和阴性预测值达89%，加入ApoE后预测值提升，不确定风险患者比例降低 [6] - 公司对4326个“真实世界样本”分类，42%高可能性、51%低可能性、7%不确定PET阳性可能性 [7] - 研究人群有显著种族多样性，但未评估非AD痴呆病因下生物标志物性能 [9] 检测优势 - 随着人口老龄化和新疗法出现，新检测能满足可扩展、高容量评估AD需求，符合CEOi性能标准，可让医生更有信心治疗患者并避免不必要检测 [8] - 与淀粉样PET成像和脑脊液检测相比，血液检测更便宜、非侵入性且不依赖专家 [8] 检测可及性 - 除纽约外美国医生可订购该检测，患者凭医嘱可通过公司网络采血，样本将送往加州实验室检测 [10] 行业背景 - 近700万美国人患阿尔茨海默病，预计到2060年达1400万，约12 - 18%六十岁以上成年人有轻度认知障碍 [11] - 77%医生认为新疗法将使阿尔茨海默病成为可管理慢性病，94%医生认为血液检测对医疗系统更具成本效益 [11] 公司概况 - 公司致力于开发创新先进诊断方法评估AD和其他脑部疾病 [12] - 公司在医疗生态系统工作，提供诊断见解，服务众多美国成年人、医生和医院 [13]

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collectionQuest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screeningNew solution follows company's launch of GTI self-collection option for several STIs and related conditions ...

About Quest Diagnostics SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide di ...